Article
Medicine, General & Internal
Giulia Scioscia, Pasquale Tondo, Santi Nolasco, Corrado Pelaia, Giovanna Elisiana Carpagnano, Maria Filomena Caiaffa, Giuseppe Valenti, Angelantonio Maglio, Francesco Papia, Massimo Triggiani, Nunzio Crimi, Girolamo Pelaia, Alessandro Vatrella, Maria Pia Foschino Barbaro, Claudia Crimi
Summary: This study aimed to evaluate the effectiveness of switching from mepolizumab to benralizumab in patients with severe eosinophilic asthma who had a sub-optimal response. The results show that switching treatment significantly improved asthma control, reduced blood eosinophil levels, and decreased exacerbation frequency. This switch was particularly effective for patients with nasal polyposis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Hideyasu Shimizu, Masamichi Hayashi, Hisayuki Kato, Mitsuru Nakagawa, Kazuyoshi Imaizumi, Mitsushi Okazawa
Summary: A case study reported a female patient with poor response to benralizumab and mepolizumab treatment, with improvements seen after treatment switching but still accompanied by adverse reactions. Analysis suggests that interleukin-13 may play a key role in the development of related diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Claudia Landi, Paolo Cameli, Lorenza Vantaggiato, Laura Bergantini, Miriana D'Alessandro, Marco Perruzza, Alfonso Carleo, Enxhi Shaba, Fabrizio Di Giuseppe, Stefania Angelucci, Elena Bargagli, Luca Bini
Summary: Severe eosinophilic asthma is associated with Th2 airway inflammation and elevated proinflammatory cytokines like IL-5. Precision therapies, including Benralizumab and Mepolizumab, have shown effectiveness in improving asthma symptoms and reducing steroid use. Differential proteomic analysis of patients treated with these therapies revealed up-regulation of antioxidant ceruloplasmin proteins after one month of Benralizumab treatment, indicating potential reduction in oxidative stress compared to Mepolizumab therapy.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
(2021)
Article
Respiratory System
David Langton, John Politis, Taya Collyer, Su-Wei Khung, Philip Bardin
Summary: In severe eosinophilic asthmatics, benralizumab treatment is more effective than mepolizumab in reducing exacerbations, improving FEV1, and depleting blood eosinophils.
Article
Health Care Sciences & Services
Jose A. Canas, Marcela Valverde-Monge, Jose M. Rodrigo-Munoz, Beatriz Sastre, Marta Gil-Martinez, Raquel Garcia-Latorre, Manuel J. Rial, Aida Gomez-Cardenosa, Mar Fernandez-Nieto, Erwin J. Pinillos-Robles, Maria J. Rodriguez-Nieto, Nicolas Gonzalez-Mangado, Joaquin Sastre, Victoria del Pozo
Summary: This study found altered expression of miR-1246, miR-5100 and miR-338-3p after eight weeks of benralizumab administration in severe eosinophilic asthmatic patients, which could be used as early response markers. These miRNAs are regulators of the MAPK signaling pathway, potentially modulating target genes implicated in asthma.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Yasuhiko Koga, Haruka Aoki-Saito, Yosuke Kamide, Makiko Sato, Hiroaki Tsurumaki, Masakiyo Yatomi, Tamotsu Ishizuka, Takeshi Hisada
Summary: Benralizumab, an IL-5 antibody biologic, has shown efficacy in treating severe asthma and EGPA. It has the ability to bind to IL-5 alpha receptors and effectively eliminate eosinophils. Studies have demonstrated that benralizumab treatment can reduce oral corticosteroid doses and achieve remission in some refractory cases. It is considered safe and tolerable in different age groups.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Hideyasu Yamada, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi, Hironori Masuko, Yohei Yatagai, Takefumi Saito, Nobuyuki Hizawa
Summary: This study investigated the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab, finding a correlation between improvement in FEV1 and increased Type 2-related inflammatory parameters, while no correlation was found with ACT improvement. A cluster analysis identified 5 distinct phenotypes of severe eosinophilic asthma, with the most responsive phenotype characterized by minimal blood eosinophils, moderate increases in total IgE and FeNO, and minimal smoking exposure.
Article
Critical Care Medicine
Joanne E. Kavanagh, Andrew P. Hearn, Jaideep Dhariwal, Grainne d'Ancona, Abdel Douiri, Cris Roxas, Mariana Fernandes, Linda Green, Louise Thomson, Alexandra M. Nanzer, Brian D. Kent, David J. Jackson
Summary: In patients with severe eosinophilic asthma treated with benralizumab, a significant reduction in asthma exacerbation rates was observed, with a subset of patients achieving super response. Blood eosinophil count increase was associated with treatment nonresponse.
Article
Allergy
Katrien Eger, Johannes A. Kroes, Anneke ten Brinke, Elisabeth H. Bel
Summary: The study found that after 2 years of anti-IL-5 treatment, a favorable response was observed in the majority of severe asthma patients, including partial and super responders. Most partial responders showed impaired lung function or uncontrolled sinonasal disease.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Medicine, General & Internal
Fatma Merve Tepetam, Ali Burkan Akyildiz, Seyma Ozden, Cihan Orcen, Tugce Yakut, Ozge Atik
Summary: This study compared the clinical, spirometric, and inflammatory efficacy of omalizumab and mepolizumab in atopic and eosinophilic overlap severe asthma patients. The results showed that there was no difference in terms of reduction in attacks and improvement in clinical control between the two biologics. However, mepolizumab treatment significantly reduced eosinophil levels and showed a greater improvement in lung function. Eosinophil counts did not affect the responder patient rates for either biological condition.
Article
Biochemistry & Molecular Biology
Lorenza Vantaggiato, Paolo Cameli, Laura Bergantini, Miriana D'Alessandro, Enxhi Shaba, Alfonso Carleo, Fabrizio Di Giuseppe, Stefania Angelucci, Guido Sebastiani, Francesco Dotta, Luca Bini, Elena Bargagli, Claudia Landi
Summary: This study used proteomic analysis to examine serum samples from patients with severe eosinophilic asthma at 1 and 6 months after two different treatments, as well as serum samples from healthy subjects. The analysis revealed 82 protein differences among the different conditions. Among the identified proteins, APOAI, APOC-II, and APOC-III were upregulated after 6 months of benralizumab treatment, plasminogen was upregulated after 6 months of both treatments, and ceruloplasmin was upregulated after 1 month of benralizumab and further increased after 6 months of mepolizumab. Enrichment analysis indicated that the identified proteins were mainly related to lipid metabolism and transport, blood coagulation, and ECM remodeling.
Article
Multidisciplinary Sciences
Giovanna Elisiana Carpagnano, Emanuela Resta, Massimiliano Povero, Corrado Pelaia, Mariella D'Amato, Nunzio Crimi, Nicola Scichilone, Giulia Scioscia, Onofrio Resta, Cecilia Calabrese, Girolamo Pelaia, Maria Pia Foschino Barbaro
Summary: The study evaluated the clinical and economic impact of switching from omalizumab to mepolizumab in severe asthma patients. Results showed that switching to mepolizumab improved all clinical outcomes, reduced exacerbation rates, decreased steroid-dependent patients, and reduced lost working days. The incremental cost due to drug therapy was offset by savings in other cost items.
SCIENTIFIC REPORTS
(2021)
Article
Allergy
Ayobami Akenroye, Grace Lassiter, John W. Jackson, Corinne Keet, Jodi Segal, G. Caleb Alexander, Hwanhee Hong
Summary: There are minimal differences in the efficacy and safety of mepolizumab, benralizumab, and dupilumab in individuals with severe eosinophilic asthma.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Allergy
Fred Fyles, Amy Nuttall, Hannah Joplin, Hassan Burhan
Summary: This study demonstrates that benralizumab and mepolizumab can significantly improve OCS use, annual exacerbation rate, and asthma control in real-world cohorts of patients with severe eosinophilic asthma (SEA) for up to 36 months, providing insights into the long-term use of these medications for SEA.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Allergy
Giorgio Walter Canonica, Tim W. Harrison, Pascal Chanez, Francesco Menzella, Renaud Louis, Borja G. Cosio, Njira L. Lugogo, Arjun Mohan, Annie Burden, Esther Garcia Gil
Summary: The study showed that benralizumab can improve symptoms of NP and asthma outcomes in patients with severe, eosinophilic asthma and NP, with better effects observed in patients with high baseline SNOT-22 scores.
Article
Biochemistry & Molecular Biology
Lorenza Vantaggiato, Enxhi Shaba, Paolo Cameli, Laura Bergantini, Miriana d'Alessandro, Alfonso Carleo, Giusy Montuori, Luca Bini, Elena Bargagli, Claudia Landi
Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic and irreversible fibrosing interstitial pneumonia of unknown cause. IPF increases the risk of lung cancer (LC), and the two diseases share similar risk factors and pathogenic pathways. A proteomic study on bronchoalveolar lavage fluid (BALF) samples identified dysregulated proteins related to inflammation, immune response, lipid metabolism, and cell adhesion in LC associated with IPF (LC-IPF) patients. These potential biomarkers could potentially improve the management of LC-IPF.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Tommaso Pianigiani, Lorenzo Alderighi, Martina Meocci, Maddalena Messina, Beatrice Perea, Simona Luzzi, Laura Bergantini, Miriana D'Alessandro, Rosa Metella Refini, Elena Bargagli, Paolo Cameli
Summary: Through a systematic review of published articles, it was found that FeNO plays an important role as a biomarker in severe asthmatic patients undergoing biologic treatment. Higher baseline FeNO levels are associated with better clinical control and lower exacerbation rates. FeNO during biologic treatment can help predict clinical worsening and differentiate eosinophilic from non-eosinophilic exacerbations.
Article
Medicine, General & Internal
Francesco Gentili, Vito Di Martino, Marta Forestieri, Francesco Mazzei, Susanna Guerrini, Elena Bargagli, Antonietta Gerardina Sisinni, Luca Volterrani, Maria Antonietta Mazzei
Summary: The aim of this study was to determine the incidence of PPFE and evaluate its distribution, severity, and progression on HRCT exams of the chest. The results showed a relatively high incidence of PPFE in routine clinical practice, with some cases demonstrating disease progression. Further research is needed to understand why some cases progress while others remain stable.
Article
Biochemistry & Molecular Biology
Paolo Cameli, Elena Pordon, Miriana d'Alessandro, Maria Laura Marzi, Lucrezia Galasso, Cesare Biuzzi, Laura Bergantini, Elena Bargagli, Sabino Scolletta, Federico Franchi
Summary: This study evaluated the performance of serum MR-proADM as a prognostic biomarker in hospitalized COVID-19 patients. It showed that MR-proADM levels were higher in non-survivors and those requiring respiratory support. The combination of MR-proADM, KL-6, and IL-6 improved the accuracy of predicting death or ICU admission.
Article
Biochemistry & Molecular Biology
Miriana d'Alessandro, Laura Bergantini, Sara Gangi, Edoardo Conticini, Dalila Cavallaro, Paolo Cameli, Fabrizio Mezzasalma, Luca Cantarini, Bruno Frediani, Elena Bargagli
Summary: This study compared the expression of T and B cell subsets in sarcoidosis and B-mediated rheumatic diseases. They found significant differences in 15 cell subsets between sarcoidosis, rheumatic disorders, and controls. Principal components analysis and decision tree analysis were used to distinguish different diseases. This study sheds light on the immune cell profile and provides potential for biological therapies in treating sarcoidosis.
Article
Biochemistry & Molecular Biology
Enxhi Shaba, Claudia Landi, Carlotta Marzocchi, Lorenza Vantaggiato, Luca Bini, Claudia Ricci, Silvia Cantara
Summary: Through proteomic analysis of Dsup-transfected human cells, we discover that Dsup activates several mechanisms involved in response to UV-C stress, including the unfolded protein response, mRNA processing and stability, cytoplasmic stress granules, DNA damage response, and telomere maintenance. These findings enhance our understanding of Dsup-mediated protective mechanisms and expand our knowledge of the molecular mechanisms against UV-C stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Miriana d'Alessandro, Laura Bergantini, Sara Gangi, Paolo Cameli, Martina Armati, Matteo Fanetti, Fabrizio Mezzasalma, Stefano Baglioni, Elena Bargagli
Summary: This study aimed to evaluate and compare T, B, and NK cell subsets in the alveolar compartment, lymph nodes, and bloodstream of sarcoidosis patients. The results showed enrichment of certain cell populations in the bloodstream, alveolar compartment, and lymph nodes. This study further supports the multisystemic nature of sarcoidosis and highlights the low level of immune cells in the peripheral blood of patients. Overall, the study has significant importance in understanding the immune responses associated with sarcoidosis development and progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Laura Bergantini, Miriana d'Alessandro, Sara Gangi, Francesco Bianchi, Paolo Cameli, Beatrice Perea, Martina Meocci, Gaia Fabbri, Sofia Marrucci, Moftah Ederbali, Elena Bargagli
Summary: Coronavirus disease 2019 (COVID-19) may lead to a chronic syndrome in some patients even after the infection is resolved. Persistent cytokine dysregulation can cause long-lasting inflammation and tissue damage, resulting in a variety of debilitating symptoms. This study evaluated the value of serum biomarkers in predicting severity, prognosis, and development of post-COVID lung sequelae.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Environmental Sciences
Claudia Landi, Giulia Liberatori, Monica Puccini, Enxhi Shaba, Lorenza Vantaggiato, Sandra Vitolo, Ilaria Corsi, Luca Bini
Summary: The use of sewage sludge (SL) and hydrochar (HC) in agriculture for soil conditioning and crop fertilization is common, but concerns about safety for human and environmental health have arisen due to the presence of toxic compounds. This study aimed to assess the suitability of proteomics and bioanalytical tools for evaluating the effects of SL and HC on human and environmental safety. By analyzing cell cultures using the DR-CALUX & REG; bioassay, we identified differentially abundant proteins after exposure to SL and HC, revealing potential links to dioxin effects, cancer, and neurological disorders. This combined approach represents an advancement in the assessment of complex mixtures like SL and HC.
SCIENCE OF THE TOTAL ENVIRONMENT
(2023)
